MedTrace Logo

CSII Versus MDI in Pregnant Women With Type 2 Diabetes

NCT05001815 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-11-30

No results posted yet for this study

Summary

The primary objective of the study is to determine if continuous subcutaneous insulin infusion (CSII) can improve glycemic control in women with type 2 diabetes (T2D) who are pregnant.

Conditions

Interventions

DEVICE

Continuous subcutaneous insulin infusion (CSII)

The CSII device used in this study has access to mobile phone, however, without CGM enhanced function

DEVICE

Multiple daily insulin injection (MDI)

Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2023-08-01
Completion
2023-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05001815 on ClinicalTrials.gov